Joint SGCC-CSI
Gastric Cancer Seminar
PRL3-zumab, A First-In-Class Humanized Antibody for Cancer Therapy

Speaker: Prof. Qi Zeng
Date: 3 October 2017 (Tuesday)
Time: 5-6PM
Venue: NUS Centre for Translational Medicine, Block MD6, #01-01B
Moderator: Prof. Jimmy So Bok Yan

Novel, tumor-specific drugs are urgently needed to improve cancer therapies. In 1998, we identified Intracellular PRL-3 (Phosphatase of Regenerating Liver 3). In 2001, Vogelstein Lab from Johns Hopkins first reported PRL-3 is associated with Colon Cancer Metastasis. Conventionally, PRL-3 small molecular inhibitors shall be used to block tumor over-expressing Intracellular PRL-3 oncoprotein. To reduce side-effects for anti-cancer, our group has been working at the forefront of unconventional antibody therapy targeting Intracellular oncoproteins using several animal models since 2006. In recent years, we generated PRL3-zumab to specifically block PRL-3 positive (but not PRL-3 negative) orthotopic Gastric tumors in mice. After surgical removing of PRL-3 positive xenograft tumors, we use PRL3-zumab to prevent cancer recurrences. In this talk, I will discuss the molecular mechanism of action (MOA) on how PRL-3 antibody could target intracellular PRL-3 antigen in tumors. Collaborating with NUHS clinicians, we have PRL3-zumab now in NUHS-IIT for safety clinical trials. We are urgently looking for PRL-3 positive cancer patients to be treated with PRL3-zumab to achieve therapeutic efficacies in humans.

To register, please contact Bryan Choo at mdccpb@nus.edu.sg